nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclosporine—systemic lupus erythematosus—psoriasis	0.282	0.514	CtDrD
Cyclosporine—rheumatoid arthritis—psoriasis	0.266	0.486	CtDrD
Cyclosporine—ABCC10—Methotrexate—psoriasis	0.0148	0.0508	CbGbCtD
Cyclosporine—CYP2C8—Tazarotene—psoriasis	0.0137	0.0471	CbGbCtD
Cyclosporine—CYP3A5—Beclomethasone—psoriasis	0.0132	0.0455	CbGbCtD
Cyclosporine—SLCO1B1—Mycophenolate mofetil—psoriasis	0.012	0.0412	CbGbCtD
Cyclosporine—SLCO1A2—Prednisolone—psoriasis	0.0107	0.037	CbGbCtD
Cyclosporine—ABCC2—Mycophenolate mofetil—psoriasis	0.0105	0.0362	CbGbCtD
Cyclosporine—SLCO1A2—Hydrocortisone—psoriasis	0.0102	0.035	CbGbCtD
Cyclosporine—SLCO1A2—Prednisone—psoriasis	0.0101	0.0349	CbGbCtD
Cyclosporine—ABCB11—Dexamethasone—psoriasis	0.00998	0.0344	CbGbCtD
Cyclosporine—ABCG2—Mycophenolate mofetil—psoriasis	0.00951	0.0327	CbGbCtD
Cyclosporine—ABCC3—Methotrexate—psoriasis	0.00928	0.0319	CbGbCtD
Cyclosporine—ABCG2—Hydrocortisone—psoriasis	0.00763	0.0263	CbGbCtD
Cyclosporine—SLCO1A2—Dexamethasone—psoriasis	0.00633	0.0218	CbGbCtD
Cyclosporine—CYP2D6—Hydroxyurea—psoriasis	0.00615	0.0212	CbGbCtD
Cyclosporine—CYP2C8—Cholecalciferol—psoriasis	0.00584	0.0201	CbGbCtD
Cyclosporine—ABCC1—Methotrexate—psoriasis	0.0057	0.0196	CbGbCtD
Cyclosporine—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.00564	0.0194	CbGbCtD
Cyclosporine—CYP3A7—Hydrocortisone—psoriasis	0.00564	0.0194	CbGbCtD
Cyclosporine—CYP3A5—Mycophenolate mofetil—psoriasis	0.00527	0.0181	CbGbCtD
Cyclosporine—ABCC2—Dexamethasone—psoriasis	0.00525	0.0181	CbGbCtD
Cyclosporine—SLCO1A2—Methotrexate—psoriasis	0.00509	0.0175	CbGbCtD
Cyclosporine—CYP2C8—Mycophenolate mofetil—psoriasis	0.00506	0.0174	CbGbCtD
Cyclosporine—CYP2C19—Cholecalciferol—psoriasis	0.0049	0.0169	CbGbCtD
Cyclosporine—SLCO1B1—Methotrexate—psoriasis	0.0048	0.0165	CbGbCtD
Cyclosporine—ABCG2—Dexamethasone—psoriasis	0.00474	0.0163	CbGbCtD
Cyclosporine—CYP3A4—Calcitriol—psoriasis	0.0046	0.0158	CbGbCtD
Cyclosporine—CYP3A5—Hydrocortisone—psoriasis	0.00423	0.0145	CbGbCtD
Cyclosporine—ABCC2—Methotrexate—psoriasis	0.00422	0.0145	CbGbCtD
Cyclosporine—CYP2C9—Cholecalciferol—psoriasis	0.00407	0.014	CbGbCtD
Cyclosporine—CYP2C8—Hydrocortisone—psoriasis	0.00406	0.014	CbGbCtD
Cyclosporine—ABCG2—Methotrexate—psoriasis	0.00381	0.0131	CbGbCtD
Cyclosporine—CYP2D6—Cholecalciferol—psoriasis	0.00373	0.0128	CbGbCtD
Cyclosporine—CYP3A4—Methoxsalen—psoriasis	0.00358	0.0123	CbGbCtD
Cyclosporine—CYP3A7—Dexamethasone—psoriasis	0.0035	0.0121	CbGbCtD
Cyclosporine—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0035	0.0121	CbGbCtD
Cyclosporine—ABCB1—Mycophenolate mofetil—psoriasis	0.00343	0.0118	CbGbCtD
Cyclosporine—CYP2C19—Prednisone—psoriasis	0.0034	0.0117	CbGbCtD
Cyclosporine—SLC22A6—Methotrexate—psoriasis	0.00309	0.0106	CbGbCtD
Cyclosporine—ABCB1—Betamethasone—psoriasis	0.00294	0.0101	CbGbCtD
Cyclosporine—ABCB1—Prednisolone—psoriasis	0.0029	0.00999	CbGbCtD
Cyclosporine—ABCB1—Hydrocortisone—psoriasis	0.00275	0.00947	CbGbCtD
Cyclosporine—ABCB1—Prednisone—psoriasis	0.00274	0.00943	CbGbCtD
Cyclosporine—CYP3A5—Dexamethasone—psoriasis	0.00263	0.00905	CbGbCtD
Cyclosporine—CYP2C8—Dexamethasone—psoriasis	0.00253	0.0087	CbGbCtD
Cyclosporine—CYP3A4—Cholecalciferol—psoriasis	0.00237	0.00815	CbGbCtD
Cyclosporine—CYP2C19—Dexamethasone—psoriasis	0.00212	0.0073	CbGbCtD
Cyclosporine—CYP3A4—Triamcinolone—psoriasis	0.00205	0.00707	CbGbCtD
Cyclosporine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00205	0.00707	CbGbCtD
Cyclosporine—CYP2C9—Dexamethasone—psoriasis	0.00176	0.00607	CbGbCtD
Cyclosporine—CYP3A4—Betamethasone—psoriasis	0.00176	0.00606	CbGbCtD
Cyclosporine—CYP3A4—Prednisolone—psoriasis	0.00174	0.00598	CbGbCtD
Cyclosporine—ABCB1—Dexamethasone—psoriasis	0.00171	0.00589	CbGbCtD
Cyclosporine—CYP3A4—Hydrocortisone—psoriasis	0.00165	0.00567	CbGbCtD
Cyclosporine—CYP3A4—Prednisone—psoriasis	0.00164	0.00565	CbGbCtD
Cyclosporine—CYP2D6—Dexamethasone—psoriasis	0.00161	0.00555	CbGbCtD
Cyclosporine—ABCB1—Methotrexate—psoriasis	0.00137	0.00473	CbGbCtD
Cyclosporine—FKBP4—Alfacalcidol—Calcipotriol—psoriasis	0.00113	0.416	CbGdCrCtD
Cyclosporine—CYP3A4—Dexamethasone—psoriasis	0.00103	0.00353	CbGbCtD
Cyclosporine—FKBP4—Alfacalcidol—Calcitriol—psoriasis	0.000853	0.315	CbGdCrCtD
Cyclosporine—FKBP4—Alfacalcidol—Cholecalciferol—psoriasis	0.000725	0.268	CbGdCrCtD
Cyclosporine—FKBP1A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.93e-05	0.000795	CbGpPWpGaD
Cyclosporine—PPP3CA—Innate Immune System—HLA-B—psoriasis	2.92e-05	0.000792	CbGpPWpGaD
Cyclosporine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	2.91e-05	0.000789	CbGpPWpGaD
Cyclosporine—ABCC3—Metabolism—NDUFA5—psoriasis	2.89e-05	0.000783	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—HLA-C—psoriasis	2.88e-05	0.00078	CbGpPWpGaD
Cyclosporine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	2.84e-05	0.000772	CbGpPWpGaD
Cyclosporine—FKBP1A—Spinal Cord Injury—TP53—psoriasis	2.84e-05	0.000771	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—TNFAIP3—psoriasis	2.84e-05	0.000771	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—IL10—psoriasis	2.83e-05	0.000767	CbGpPWpGaD
Cyclosporine—FKBP1A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.82e-05	0.000765	CbGpPWpGaD
Cyclosporine—ABCB11—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.81e-05	0.000762	CbGpPWpGaD
Cyclosporine—PPP3CA—MAPK Signaling Pathway—TP53—psoriasis	2.76e-05	0.00075	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—IL4—psoriasis	2.75e-05	0.000746	CbGpPWpGaD
Cyclosporine—ABCC3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.69e-05	0.00073	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—HLA-B—psoriasis	2.69e-05	0.00073	CbGpPWpGaD
Cyclosporine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	2.69e-05	0.000729	CbGpPWpGaD
Cyclosporine—ABCC3—Transmembrane transport of small molecules—CP—psoriasis	2.68e-05	0.000728	CbGpPWpGaD
Cyclosporine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.68e-05	0.000728	CbGpPWpGaD
Cyclosporine—FKBP1A—Spinal Cord Injury—IL6—psoriasis	2.6e-05	0.000706	CbGpPWpGaD
Cyclosporine—PPP3CA—Innate Immune System—CRP—psoriasis	2.58e-05	0.0007	CbGpPWpGaD
Cyclosporine—ABCB11—Metabolism—CYP2S1—psoriasis	2.56e-05	0.000695	CbGpPWpGaD
Cyclosporine—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.56e-05	0.000694	CbGpPWpGaD
Cyclosporine—ABCC3—Transmembrane transport of small molecules—CARM1—psoriasis	2.56e-05	0.000694	CbGpPWpGaD
Cyclosporine—SLCO1A2—Metabolism—NDUFA5—psoriasis	2.51e-05	0.000682	CbGpPWpGaD
Cyclosporine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	2.5e-05	0.000679	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—HLA-A—psoriasis	2.49e-05	0.000676	CbGpPWpGaD
Cyclosporine—ABCC3—Metabolism—CYP2S1—psoriasis	2.45e-05	0.000666	CbGpPWpGaD
Cyclosporine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.45e-05	0.000665	CbGpPWpGaD
Cyclosporine—PPP3CA—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	2.43e-05	0.000658	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—HLA-E—psoriasis	2.39e-05	0.000648	CbGpPWpGaD
Cyclosporine—PPP3CA—Innate Immune System—NFKBIA—psoriasis	2.35e-05	0.000639	CbGpPWpGaD
Cyclosporine—SLCO1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.34e-05	0.000636	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—CCL20—psoriasis	2.34e-05	0.000635	CbGpPWpGaD
Cyclosporine—SLCO1A2—Transmembrane transport of small molecules—CP—psoriasis	2.34e-05	0.000634	CbGpPWpGaD
Cyclosporine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	2.28e-05	0.000618	CbGpPWpGaD
Cyclosporine—SLC10A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.28e-05	0.000618	CbGpPWpGaD
Cyclosporine—Hepatobiliary disease—Methotrexate—psoriasis	2.26e-05	0.000185	CcSEcCtD
Cyclosporine—ABCC1—Metabolism—NDUFA5—psoriasis	2.26e-05	0.000614	CbGpPWpGaD
Cyclosporine—Dizziness—Mycophenolic acid—psoriasis	2.26e-05	0.000185	CcSEcCtD
Cyclosporine—Epistaxis—Methotrexate—psoriasis	2.26e-05	0.000185	CcSEcCtD
Cyclosporine—Paraesthesia—Prednisolone—psoriasis	2.26e-05	0.000185	CcSEcCtD
Cyclosporine—Mental disorder—Prednisone—psoriasis	2.25e-05	0.000184	CcSEcCtD
Cyclosporine—Malnutrition—Prednisone—psoriasis	2.24e-05	0.000183	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	2.24e-05	0.000183	CcSEcCtD
Cyclosporine—Hyperhidrosis—Triamcinolone—psoriasis	2.24e-05	0.000183	CcSEcCtD
Cyclosporine—SLCO1A2—Transmembrane transport of small molecules—CARM1—psoriasis	2.23e-05	0.000605	CbGpPWpGaD
Cyclosporine—Convulsion—Dexamethasone—psoriasis	2.23e-05	0.000182	CcSEcCtD
Cyclosporine—Convulsion—Betamethasone—psoriasis	2.23e-05	0.000182	CcSEcCtD
Cyclosporine—Feeling abnormal—Mycophenolate mofetil—psoriasis	2.22e-05	0.000182	CcSEcCtD
Cyclosporine—Insomnia—Hydrocortisone—psoriasis	2.22e-05	0.000182	CcSEcCtD
Cyclosporine—Hypertension—Dexamethasone—psoriasis	2.22e-05	0.000182	CcSEcCtD
Cyclosporine—Hypertension—Betamethasone—psoriasis	2.22e-05	0.000182	CcSEcCtD
Cyclosporine—Paraesthesia—Hydrocortisone—psoriasis	2.21e-05	0.00018	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	2.2e-05	0.00018	CcSEcCtD
Cyclosporine—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	2.2e-05	0.000596	CbGpPWpGaD
Cyclosporine—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.19e-05	0.000595	CbGpPWpGaD
Cyclosporine—Myalgia—Dexamethasone—psoriasis	2.19e-05	0.000179	CcSEcCtD
Cyclosporine—Myalgia—Betamethasone—psoriasis	2.19e-05	0.000179	CcSEcCtD
Cyclosporine—Anxiety—Betamethasone—psoriasis	2.18e-05	0.000178	CcSEcCtD
Cyclosporine—Anxiety—Dexamethasone—psoriasis	2.18e-05	0.000178	CcSEcCtD
Cyclosporine—Vomiting—Mycophenolic acid—psoriasis	2.17e-05	0.000178	CcSEcCtD
Cyclosporine—Discomfort—Betamethasone—psoriasis	2.16e-05	0.000177	CcSEcCtD
Cyclosporine—Discomfort—Dexamethasone—psoriasis	2.16e-05	0.000177	CcSEcCtD
Cyclosporine—Dyspepsia—Hydrocortisone—psoriasis	2.16e-05	0.000177	CcSEcCtD
Cyclosporine—Haemoglobin—Methotrexate—psoriasis	2.16e-05	0.000177	CcSEcCtD
Cyclosporine—Rash—Mycophenolic acid—psoriasis	2.15e-05	0.000176	CcSEcCtD
Cyclosporine—Dermatitis—Mycophenolic acid—psoriasis	2.15e-05	0.000176	CcSEcCtD
Cyclosporine—Pain—Prednisolone—psoriasis	2.15e-05	0.000176	CcSEcCtD
Cyclosporine—Hepatitis—Methotrexate—psoriasis	2.15e-05	0.000176	CcSEcCtD
Cyclosporine—Haemorrhage—Methotrexate—psoriasis	2.15e-05	0.000176	CcSEcCtD
Cyclosporine—SLCO1B1—Metabolism—NDUFA5—psoriasis	2.15e-05	0.000583	CbGpPWpGaD
Cyclosporine—Urticaria—Mycophenolate mofetil—psoriasis	2.14e-05	0.000175	CcSEcCtD
Cyclosporine—Headache—Mycophenolic acid—psoriasis	2.14e-05	0.000175	CcSEcCtD
Cyclosporine—SLCO1A2—Metabolism—CYP2S1—psoriasis	2.14e-05	0.00058	CbGpPWpGaD
Cyclosporine—Decreased appetite—Hydrocortisone—psoriasis	2.14e-05	0.000175	CcSEcCtD
Cyclosporine—Pharyngitis—Methotrexate—psoriasis	2.13e-05	0.000174	CcSEcCtD
Cyclosporine—Body temperature increased—Mycophenolate mofetil—psoriasis	2.13e-05	0.000174	CcSEcCtD
Cyclosporine—Abdominal pain—Mycophenolate mofetil—psoriasis	2.13e-05	0.000174	CcSEcCtD
Cyclosporine—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	2.13e-05	0.000577	CbGpPWpGaD
Cyclosporine—Urinary tract disorder—Methotrexate—psoriasis	2.12e-05	0.000174	CcSEcCtD
Cyclosporine—SLC10A1—Metabolism—CARM1—psoriasis	2.12e-05	0.000576	CbGpPWpGaD
Cyclosporine—Gastrointestinal disorder—Hydrocortisone—psoriasis	2.12e-05	0.000173	CcSEcCtD
Cyclosporine—Fatigue—Hydrocortisone—psoriasis	2.12e-05	0.000173	CcSEcCtD
Cyclosporine—Vision blurred—Prednisone—psoriasis	2.11e-05	0.000173	CcSEcCtD
Cyclosporine—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.11e-05	0.000572	CbGpPWpGaD
Cyclosporine—Urethral disorder—Methotrexate—psoriasis	2.11e-05	0.000172	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Triamcinolone—psoriasis	2.11e-05	0.000172	CcSEcCtD
Cyclosporine—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	2.1e-05	0.00057	CbGpPWpGaD
Cyclosporine—Pain—Hydrocortisone—psoriasis	2.1e-05	0.000172	CcSEcCtD
Cyclosporine—Oedema—Betamethasone—psoriasis	2.1e-05	0.000172	CcSEcCtD
Cyclosporine—Oedema—Dexamethasone—psoriasis	2.1e-05	0.000172	CcSEcCtD
Cyclosporine—Anaphylactic shock—Betamethasone—psoriasis	2.1e-05	0.000172	CcSEcCtD
Cyclosporine—Anaphylactic shock—Dexamethasone—psoriasis	2.1e-05	0.000172	CcSEcCtD
Cyclosporine—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	2.09e-05	0.000568	CbGpPWpGaD
Cyclosporine—Insomnia—Triamcinolone—psoriasis	2.09e-05	0.000171	CcSEcCtD
Cyclosporine—Infection—Betamethasone—psoriasis	2.08e-05	0.00017	CcSEcCtD
Cyclosporine—Infection—Dexamethasone—psoriasis	2.08e-05	0.00017	CcSEcCtD
Cyclosporine—Ill-defined disorder—Prednisone—psoriasis	2.08e-05	0.00017	CcSEcCtD
Cyclosporine—Paraesthesia—Triamcinolone—psoriasis	2.08e-05	0.00017	CcSEcCtD
Cyclosporine—Feeling abnormal—Prednisolone—psoriasis	2.07e-05	0.000169	CcSEcCtD
Cyclosporine—Visual impairment—Methotrexate—psoriasis	2.07e-05	0.000169	CcSEcCtD
Cyclosporine—Anaemia—Prednisone—psoriasis	2.07e-05	0.000169	CcSEcCtD
Cyclosporine—Dyspnoea—Triamcinolone—psoriasis	2.06e-05	0.000169	CcSEcCtD
Cyclosporine—Nervous system disorder—Betamethasone—psoriasis	2.06e-05	0.000168	CcSEcCtD
Cyclosporine—Nervous system disorder—Dexamethasone—psoriasis	2.06e-05	0.000168	CcSEcCtD
Cyclosporine—Agitation—Prednisone—psoriasis	2.06e-05	0.000168	CcSEcCtD
Cyclosporine—Thrombocytopenia—Betamethasone—psoriasis	2.05e-05	0.000168	CcSEcCtD
Cyclosporine—Thrombocytopenia—Dexamethasone—psoriasis	2.05e-05	0.000168	CcSEcCtD
Cyclosporine—Angioedema—Prednisone—psoriasis	2.05e-05	0.000167	CcSEcCtD
Cyclosporine—Dyspepsia—Triamcinolone—psoriasis	2.04e-05	0.000166	CcSEcCtD
Cyclosporine—Nausea—Mycophenolic acid—psoriasis	2.03e-05	0.000166	CcSEcCtD
Cyclosporine—Hyperhidrosis—Dexamethasone—psoriasis	2.03e-05	0.000166	CcSEcCtD
Cyclosporine—Hyperhidrosis—Betamethasone—psoriasis	2.03e-05	0.000166	CcSEcCtD
Cyclosporine—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	2.03e-05	0.000551	CbGpPWpGaD
Cyclosporine—SLC10A2—Metabolism—CAT—psoriasis	2.02e-05	0.000549	CbGpPWpGaD
Cyclosporine—Feeling abnormal—Hydrocortisone—psoriasis	2.02e-05	0.000166	CcSEcCtD
Cyclosporine—Malaise—Prednisone—psoriasis	2.02e-05	0.000165	CcSEcCtD
Cyclosporine—Vertigo—Prednisone—psoriasis	2.01e-05	0.000165	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Hydrocortisone—psoriasis	2.01e-05	0.000164	CcSEcCtD
Cyclosporine—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	2e-05	0.000544	CbGpPWpGaD
Cyclosporine—Tinnitus—Methotrexate—psoriasis	2e-05	0.000164	CcSEcCtD
Cyclosporine—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2e-05	0.000544	CbGpPWpGaD
Cyclosporine—Anorexia—Dexamethasone—psoriasis	2e-05	0.000164	CcSEcCtD
Cyclosporine—Anorexia—Betamethasone—psoriasis	2e-05	0.000164	CcSEcCtD
Cyclosporine—Urticaria—Prednisolone—psoriasis	2e-05	0.000163	CcSEcCtD
Cyclosporine—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	2e-05	0.000542	CbGpPWpGaD
Cyclosporine—Fatigue—Triamcinolone—psoriasis	1.99e-05	0.000163	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—SOCS1—psoriasis	1.99e-05	0.000541	CbGpPWpGaD
Cyclosporine—ABCG2—Metabolism—NDUFA5—psoriasis	1.99e-05	0.00054	CbGpPWpGaD
Cyclosporine—Hypersensitivity—Mycophenolate mofetil—psoriasis	1.99e-05	0.000162	CcSEcCtD
Cyclosporine—SLC10A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.98e-05	0.000538	CbGpPWpGaD
Cyclosporine—Pain—Triamcinolone—psoriasis	1.98e-05	0.000162	CcSEcCtD
Cyclosporine—CYP3A7—Metabolism—NDUFA5—psoriasis	1.97e-05	0.000535	CbGpPWpGaD
Cyclosporine—Urticaria—Hydrocortisone—psoriasis	1.95e-05	0.00016	CcSEcCtD
Cyclosporine—Angiopathy—Methotrexate—psoriasis	1.95e-05	0.00016	CcSEcCtD
Cyclosporine—Abdominal pain—Hydrocortisone—psoriasis	1.94e-05	0.000159	CcSEcCtD
Cyclosporine—Body temperature increased—Hydrocortisone—psoriasis	1.94e-05	0.000159	CcSEcCtD
Cyclosporine—Convulsion—Prednisone—psoriasis	1.94e-05	0.000159	CcSEcCtD
Cyclosporine—Mediastinal disorder—Methotrexate—psoriasis	1.94e-05	0.000158	CcSEcCtD
Cyclosporine—Asthenia—Mycophenolate mofetil—psoriasis	1.93e-05	0.000158	CcSEcCtD
Cyclosporine—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.93e-05	0.000525	CbGpPWpGaD
Cyclosporine—Hypertension—Prednisone—psoriasis	1.93e-05	0.000158	CcSEcCtD
Cyclosporine—Chills—Methotrexate—psoriasis	1.93e-05	0.000158	CcSEcCtD
Cyclosporine—PPP3CA—Innate Immune System—TYK2—psoriasis	1.93e-05	0.000523	CbGpPWpGaD
Cyclosporine—ABCC1—Metabolism—CYP2S1—psoriasis	1.92e-05	0.000522	CbGpPWpGaD
Cyclosporine—Musculoskeletal discomfort—Betamethasone—psoriasis	1.91e-05	0.000156	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Dexamethasone—psoriasis	1.91e-05	0.000156	CcSEcCtD
Cyclosporine—Pruritus—Mycophenolate mofetil—psoriasis	1.91e-05	0.000156	CcSEcCtD
Cyclosporine—Arthralgia—Prednisone—psoriasis	1.91e-05	0.000156	CcSEcCtD
Cyclosporine—Myalgia—Prednisone—psoriasis	1.91e-05	0.000156	CcSEcCtD
Cyclosporine—Feeling abnormal—Triamcinolone—psoriasis	1.91e-05	0.000156	CcSEcCtD
Cyclosporine—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	1.91e-05	0.000517	CbGpPWpGaD
Cyclosporine—Anxiety—Prednisone—psoriasis	1.9e-05	0.000155	CcSEcCtD
Cyclosporine—Alopecia—Methotrexate—psoriasis	1.9e-05	0.000155	CcSEcCtD
Cyclosporine—Insomnia—Betamethasone—psoriasis	1.9e-05	0.000155	CcSEcCtD
Cyclosporine—Insomnia—Dexamethasone—psoriasis	1.9e-05	0.000155	CcSEcCtD
Cyclosporine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	1.89e-05	0.000155	CcSEcCtD
Cyclosporine—Paraesthesia—Dexamethasone—psoriasis	1.88e-05	0.000154	CcSEcCtD
Cyclosporine—Paraesthesia—Betamethasone—psoriasis	1.88e-05	0.000154	CcSEcCtD
Cyclosporine—Discomfort—Prednisone—psoriasis	1.88e-05	0.000154	CcSEcCtD
Cyclosporine—Mental disorder—Methotrexate—psoriasis	1.88e-05	0.000154	CcSEcCtD
Cyclosporine—Malnutrition—Methotrexate—psoriasis	1.87e-05	0.000153	CcSEcCtD
Cyclosporine—Hypersensitivity—Prednisolone—psoriasis	1.85e-05	0.000152	CcSEcCtD
Cyclosporine—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	1.85e-05	0.000502	CbGpPWpGaD
Cyclosporine—Dyspepsia—Betamethasone—psoriasis	1.85e-05	0.000151	CcSEcCtD
Cyclosporine—Dyspepsia—Dexamethasone—psoriasis	1.85e-05	0.000151	CcSEcCtD
Cyclosporine—Diarrhoea—Mycophenolate mofetil—psoriasis	1.84e-05	0.000151	CcSEcCtD
Cyclosporine—Urticaria—Triamcinolone—psoriasis	1.84e-05	0.00015	CcSEcCtD
Cyclosporine—Dysgeusia—Methotrexate—psoriasis	1.83e-05	0.00015	CcSEcCtD
Cyclosporine—Body temperature increased—Triamcinolone—psoriasis	1.83e-05	0.00015	CcSEcCtD
Cyclosporine—Anaphylactic shock—Prednisone—psoriasis	1.83e-05	0.000149	CcSEcCtD
Cyclosporine—Oedema—Prednisone—psoriasis	1.83e-05	0.000149	CcSEcCtD
Cyclosporine—SLCO1B1—Metabolism—CYP2S1—psoriasis	1.83e-05	0.000496	CbGpPWpGaD
Cyclosporine—Decreased appetite—Betamethasone—psoriasis	1.82e-05	0.000149	CcSEcCtD
Cyclosporine—Decreased appetite—Dexamethasone—psoriasis	1.82e-05	0.000149	CcSEcCtD
Cyclosporine—PPIA—Hemostasis—VEGFA—psoriasis	1.82e-05	0.000494	CbGpPWpGaD
Cyclosporine—Infection—Prednisone—psoriasis	1.82e-05	0.000148	CcSEcCtD
Cyclosporine—FKBP1A—Signaling Pathways—CCL20—psoriasis	1.81e-05	0.000492	CbGpPWpGaD
Cyclosporine—Gastrointestinal disorder—Dexamethasone—psoriasis	1.81e-05	0.000148	CcSEcCtD
Cyclosporine—Gastrointestinal disorder—Betamethasone—psoriasis	1.81e-05	0.000148	CcSEcCtD
Cyclosporine—Hypersensitivity—Hydrocortisone—psoriasis	1.81e-05	0.000148	CcSEcCtD
Cyclosporine—Fatigue—Dexamethasone—psoriasis	1.81e-05	0.000148	CcSEcCtD
Cyclosporine—Fatigue—Betamethasone—psoriasis	1.81e-05	0.000148	CcSEcCtD
Cyclosporine—Pain—Betamethasone—psoriasis	1.79e-05	0.000147	CcSEcCtD
Cyclosporine—Pain—Dexamethasone—psoriasis	1.79e-05	0.000147	CcSEcCtD
Cyclosporine—Nervous system disorder—Prednisone—psoriasis	1.79e-05	0.000147	CcSEcCtD
Cyclosporine—Dizziness—Mycophenolate mofetil—psoriasis	1.78e-05	0.000146	CcSEcCtD
Cyclosporine—Skin disorder—Prednisone—psoriasis	1.78e-05	0.000145	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—CD8A—psoriasis	1.77e-05	0.00048	CbGpPWpGaD
Cyclosporine—Hyperhidrosis—Prednisone—psoriasis	1.77e-05	0.000144	CcSEcCtD
Cyclosporine—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	1.76e-05	0.000479	CbGpPWpGaD
Cyclosporine—Vision blurred—Methotrexate—psoriasis	1.76e-05	0.000144	CcSEcCtD
Cyclosporine—Asthenia—Hydrocortisone—psoriasis	1.76e-05	0.000144	CcSEcCtD
Cyclosporine—PPIA—Disease—HLA-A—psoriasis	1.75e-05	0.000475	CbGpPWpGaD
Cyclosporine—PPP3CA—Innate Immune System—CD4—psoriasis	1.74e-05	0.000473	CbGpPWpGaD
Cyclosporine—Anorexia—Prednisone—psoriasis	1.74e-05	0.000142	CcSEcCtD
Cyclosporine—Pruritus—Hydrocortisone—psoriasis	1.74e-05	0.000142	CcSEcCtD
Cyclosporine—Ill-defined disorder—Methotrexate—psoriasis	1.74e-05	0.000142	CcSEcCtD
Cyclosporine—Anaemia—Methotrexate—psoriasis	1.73e-05	0.000141	CcSEcCtD
Cyclosporine—Feeling abnormal—Betamethasone—psoriasis	1.73e-05	0.000141	CcSEcCtD
Cyclosporine—Feeling abnormal—Dexamethasone—psoriasis	1.73e-05	0.000141	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Betamethasone—psoriasis	1.72e-05	0.00014	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Dexamethasone—psoriasis	1.72e-05	0.00014	CcSEcCtD
Cyclosporine—Vomiting—Mycophenolate mofetil—psoriasis	1.71e-05	0.00014	CcSEcCtD
Cyclosporine—Hypersensitivity—Triamcinolone—psoriasis	1.7e-05	0.000139	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—HLA-B—psoriasis	1.7e-05	0.000461	CbGpPWpGaD
Cyclosporine—Rash—Mycophenolate mofetil—psoriasis	1.7e-05	0.000139	CcSEcCtD
Cyclosporine—Dermatitis—Mycophenolate mofetil—psoriasis	1.7e-05	0.000139	CcSEcCtD
Cyclosporine—ABCG2—Metabolism—CYP2S1—psoriasis	1.69e-05	0.000459	CbGpPWpGaD
Cyclosporine—Headache—Mycophenolate mofetil—psoriasis	1.69e-05	0.000138	CcSEcCtD
Cyclosporine—Malaise—Methotrexate—psoriasis	1.69e-05	0.000138	CcSEcCtD
Cyclosporine—Vertigo—Methotrexate—psoriasis	1.68e-05	0.000138	CcSEcCtD
Cyclosporine—Diarrhoea—Hydrocortisone—psoriasis	1.68e-05	0.000137	CcSEcCtD
Cyclosporine—CYP3A7—Metabolism—CYP2S1—psoriasis	1.68e-05	0.000455	CbGpPWpGaD
Cyclosporine—Leukopenia—Methotrexate—psoriasis	1.68e-05	0.000137	CcSEcCtD
Cyclosporine—Urticaria—Betamethasone—psoriasis	1.67e-05	0.000136	CcSEcCtD
Cyclosporine—Urticaria—Dexamethasone—psoriasis	1.67e-05	0.000136	CcSEcCtD
Cyclosporine—Musculoskeletal discomfort—Prednisone—psoriasis	1.67e-05	0.000136	CcSEcCtD
Cyclosporine—Dizziness—Prednisolone—psoriasis	1.66e-05	0.000136	CcSEcCtD
Cyclosporine—ABCB1—Allograft Rejection—IFNG—psoriasis	1.66e-05	0.000451	CbGpPWpGaD
Cyclosporine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	1.66e-05	0.00045	CbGpPWpGaD
Cyclosporine—Asthenia—Triamcinolone—psoriasis	1.66e-05	0.000136	CcSEcCtD
Cyclosporine—Body temperature increased—Betamethasone—psoriasis	1.66e-05	0.000136	CcSEcCtD
Cyclosporine—Abdominal pain—Dexamethasone—psoriasis	1.66e-05	0.000136	CcSEcCtD
Cyclosporine—Abdominal pain—Betamethasone—psoriasis	1.66e-05	0.000136	CcSEcCtD
Cyclosporine—Body temperature increased—Dexamethasone—psoriasis	1.66e-05	0.000136	CcSEcCtD
Cyclosporine—Insomnia—Prednisone—psoriasis	1.65e-05	0.000135	CcSEcCtD
Cyclosporine—Paraesthesia—Prednisone—psoriasis	1.64e-05	0.000134	CcSEcCtD
Cyclosporine—Pruritus—Triamcinolone—psoriasis	1.64e-05	0.000134	CcSEcCtD
Cyclosporine—PPIA—Disease—APOE—psoriasis	1.63e-05	0.000443	CbGpPWpGaD
Cyclosporine—Cough—Methotrexate—psoriasis	1.63e-05	0.000134	CcSEcCtD
Cyclosporine—Dizziness—Hydrocortisone—psoriasis	1.62e-05	0.000133	CcSEcCtD
Cyclosporine—Convulsion—Methotrexate—psoriasis	1.62e-05	0.000133	CcSEcCtD
Cyclosporine—Dyspepsia—Prednisone—psoriasis	1.61e-05	0.000132	CcSEcCtD
Cyclosporine—Nausea—Mycophenolate mofetil—psoriasis	1.6e-05	0.000131	CcSEcCtD
Cyclosporine—Myalgia—Methotrexate—psoriasis	1.59e-05	0.00013	CcSEcCtD
Cyclosporine—Chest pain—Methotrexate—psoriasis	1.59e-05	0.00013	CcSEcCtD
Cyclosporine—Arthralgia—Methotrexate—psoriasis	1.59e-05	0.00013	CcSEcCtD
Cyclosporine—Decreased appetite—Prednisone—psoriasis	1.59e-05	0.00013	CcSEcCtD
Cyclosporine—Rash—Prednisolone—psoriasis	1.59e-05	0.00013	CcSEcCtD
Cyclosporine—Dermatitis—Prednisolone—psoriasis	1.58e-05	0.00013	CcSEcCtD
Cyclosporine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	1.58e-05	0.000129	CcSEcCtD
Cyclosporine—Fatigue—Prednisone—psoriasis	1.58e-05	0.000129	CcSEcCtD
Cyclosporine—Headache—Prednisolone—psoriasis	1.58e-05	0.000129	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—HLA-A—psoriasis	1.58e-05	0.000428	CbGpPWpGaD
Cyclosporine—Discomfort—Methotrexate—psoriasis	1.57e-05	0.000129	CcSEcCtD
Cyclosporine—SLC10A2—Metabolism—APOE—psoriasis	1.57e-05	0.000427	CbGpPWpGaD
Cyclosporine—Constipation—Prednisone—psoriasis	1.56e-05	0.000128	CcSEcCtD
Cyclosporine—Vomiting—Hydrocortisone—psoriasis	1.56e-05	0.000128	CcSEcCtD
Cyclosporine—PPP3CA—Innate Immune System—JUN—psoriasis	1.56e-05	0.000423	CbGpPWpGaD
Cyclosporine—Rash—Hydrocortisone—psoriasis	1.55e-05	0.000127	CcSEcCtD
Cyclosporine—Dermatitis—Hydrocortisone—psoriasis	1.55e-05	0.000127	CcSEcCtD
Cyclosporine—ABCB1—Allograft Rejection—CXCL8—psoriasis	1.55e-05	0.00042	CbGpPWpGaD
Cyclosporine—Confusional state—Methotrexate—psoriasis	1.54e-05	0.000126	CcSEcCtD
Cyclosporine—Headache—Hydrocortisone—psoriasis	1.54e-05	0.000126	CcSEcCtD
Cyclosporine—Dizziness—Triamcinolone—psoriasis	1.53e-05	0.000125	CcSEcCtD
Cyclosporine—Anaphylactic shock—Methotrexate—psoriasis	1.53e-05	0.000125	CcSEcCtD
Cyclosporine—PPIA—Disease—NOS2—psoriasis	1.52e-05	0.000413	CbGpPWpGaD
Cyclosporine—Infection—Methotrexate—psoriasis	1.52e-05	0.000124	CcSEcCtD
Cyclosporine—Feeling abnormal—Prednisone—psoriasis	1.51e-05	0.000123	CcSEcCtD
Cyclosporine—Asthenia—Dexamethasone—psoriasis	1.51e-05	0.000123	CcSEcCtD
Cyclosporine—Asthenia—Betamethasone—psoriasis	1.51e-05	0.000123	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—CRP—psoriasis	1.5e-05	0.000408	CbGpPWpGaD
Cyclosporine—PPP3CA—Innate Immune System—NFKB1—psoriasis	1.5e-05	0.000408	CbGpPWpGaD
Cyclosporine—Nervous system disorder—Methotrexate—psoriasis	1.5e-05	0.000122	CcSEcCtD
Cyclosporine—Thrombocytopenia—Methotrexate—psoriasis	1.5e-05	0.000122	CcSEcCtD
Cyclosporine—Gastrointestinal pain—Prednisone—psoriasis	1.49e-05	0.000122	CcSEcCtD
Cyclosporine—Nausea—Prednisolone—psoriasis	1.49e-05	0.000122	CcSEcCtD
Cyclosporine—Pruritus—Dexamethasone—psoriasis	1.48e-05	0.000121	CcSEcCtD
Cyclosporine—Pruritus—Betamethasone—psoriasis	1.48e-05	0.000121	CcSEcCtD
Cyclosporine—Skin disorder—Methotrexate—psoriasis	1.48e-05	0.000121	CcSEcCtD
Cyclosporine—Hyperhidrosis—Methotrexate—psoriasis	1.48e-05	0.000121	CcSEcCtD
Cyclosporine—Vomiting—Triamcinolone—psoriasis	1.47e-05	0.00012	CcSEcCtD
Cyclosporine—Nausea—Hydrocortisone—psoriasis	1.46e-05	0.000119	CcSEcCtD
Cyclosporine—Rash—Triamcinolone—psoriasis	1.46e-05	0.000119	CcSEcCtD
Cyclosporine—Dermatitis—Triamcinolone—psoriasis	1.46e-05	0.000119	CcSEcCtD
Cyclosporine—Anorexia—Methotrexate—psoriasis	1.46e-05	0.000119	CcSEcCtD
Cyclosporine—PPP3CA—Disease—HLA-A—psoriasis	1.45e-05	0.000395	CbGpPWpGaD
Cyclosporine—Urticaria—Prednisone—psoriasis	1.45e-05	0.000119	CcSEcCtD
Cyclosporine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.45e-05	0.000393	CbGpPWpGaD
Cyclosporine—Headache—Triamcinolone—psoriasis	1.45e-05	0.000118	CcSEcCtD
Cyclosporine—Abdominal pain—Prednisone—psoriasis	1.44e-05	0.000118	CcSEcCtD
Cyclosporine—Body temperature increased—Prednisone—psoriasis	1.44e-05	0.000118	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—HLA-DRB1—psoriasis	1.44e-05	0.000391	CbGpPWpGaD
Cyclosporine—Diarrhoea—Betamethasone—psoriasis	1.44e-05	0.000117	CcSEcCtD
Cyclosporine—Diarrhoea—Dexamethasone—psoriasis	1.44e-05	0.000117	CcSEcCtD
Cyclosporine—CYP3A5—Metabolism—NDUFA5—psoriasis	1.43e-05	0.000387	CbGpPWpGaD
Cyclosporine—Musculoskeletal discomfort—Methotrexate—psoriasis	1.39e-05	0.000114	CcSEcCtD
Cyclosporine—Dizziness—Dexamethasone—psoriasis	1.39e-05	0.000113	CcSEcCtD
Cyclosporine—Dizziness—Betamethasone—psoriasis	1.39e-05	0.000113	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—ICAM1—psoriasis	1.38e-05	0.000375	CbGpPWpGaD
Cyclosporine—Insomnia—Methotrexate—psoriasis	1.38e-05	0.000113	CcSEcCtD
Cyclosporine—PPIA—Hemostasis—TP53—psoriasis	1.38e-05	0.000374	CbGpPWpGaD
Cyclosporine—Nausea—Triamcinolone—psoriasis	1.37e-05	0.000112	CcSEcCtD
Cyclosporine—Paraesthesia—Methotrexate—psoriasis	1.37e-05	0.000112	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—NFKBIA—psoriasis	1.37e-05	0.000372	CbGpPWpGaD
Cyclosporine—SLC10A2—Metabolism—PPARG—psoriasis	1.37e-05	0.000372	CbGpPWpGaD
Cyclosporine—Dyspnoea—Methotrexate—psoriasis	1.36e-05	0.000111	CcSEcCtD
Cyclosporine—PPP3CA—Disease—APOE—psoriasis	1.36e-05	0.000368	CbGpPWpGaD
Cyclosporine—Somnolence—Methotrexate—psoriasis	1.36e-05	0.000111	CcSEcCtD
Cyclosporine—Hypersensitivity—Prednisone—psoriasis	1.35e-05	0.00011	CcSEcCtD
Cyclosporine—Dyspepsia—Methotrexate—psoriasis	1.34e-05	0.00011	CcSEcCtD
Cyclosporine—ABCB11—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.34e-05	0.000364	CbGpPWpGaD
Cyclosporine—Vomiting—Betamethasone—psoriasis	1.33e-05	0.000109	CcSEcCtD
Cyclosporine—Vomiting—Dexamethasone—psoriasis	1.33e-05	0.000109	CcSEcCtD
Cyclosporine—Decreased appetite—Methotrexate—psoriasis	1.33e-05	0.000109	CcSEcCtD
Cyclosporine—Rash—Dexamethasone—psoriasis	1.32e-05	0.000108	CcSEcCtD
Cyclosporine—Rash—Betamethasone—psoriasis	1.32e-05	0.000108	CcSEcCtD
Cyclosporine—Dermatitis—Dexamethasone—psoriasis	1.32e-05	0.000108	CcSEcCtD
Cyclosporine—Dermatitis—Betamethasone—psoriasis	1.32e-05	0.000108	CcSEcCtD
Cyclosporine—Gastrointestinal disorder—Methotrexate—psoriasis	1.32e-05	0.000108	CcSEcCtD
Cyclosporine—Fatigue—Methotrexate—psoriasis	1.32e-05	0.000108	CcSEcCtD
Cyclosporine—Headache—Dexamethasone—psoriasis	1.31e-05	0.000108	CcSEcCtD
Cyclosporine—Headache—Betamethasone—psoriasis	1.31e-05	0.000108	CcSEcCtD
Cyclosporine—Asthenia—Prednisone—psoriasis	1.31e-05	0.000107	CcSEcCtD
Cyclosporine—Pain—Methotrexate—psoriasis	1.31e-05	0.000107	CcSEcCtD
Cyclosporine—SLC10A1—Metabolism—CAT—psoriasis	1.3e-05	0.000354	CbGpPWpGaD
Cyclosporine—Pruritus—Prednisone—psoriasis	1.29e-05	0.000106	CcSEcCtD
Cyclosporine—PPP3CA—Signaling Pathways—SOCS1—psoriasis	1.29e-05	0.00035	CbGpPWpGaD
Cyclosporine—ABCC3—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.29e-05	0.000349	CbGpPWpGaD
Cyclosporine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.27e-05	0.000346	CbGpPWpGaD
Cyclosporine—PPP3CA—Disease—NOS2—psoriasis	1.27e-05	0.000343	CbGpPWpGaD
Cyclosporine—Feeling abnormal—Methotrexate—psoriasis	1.26e-05	0.000103	CcSEcCtD
Cyclosporine—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.26e-05	0.000341	CbGpPWpGaD
Cyclosporine—Diarrhoea—Prednisone—psoriasis	1.25e-05	0.000102	CcSEcCtD
Cyclosporine—ABCB11—Metabolism—CARM1—psoriasis	1.25e-05	0.000339	CbGpPWpGaD
Cyclosporine—Gastrointestinal pain—Methotrexate—psoriasis	1.25e-05	0.000102	CcSEcCtD
Cyclosporine—PPIA—Disease—TYK2—psoriasis	1.25e-05	0.000338	CbGpPWpGaD
Cyclosporine—Nausea—Dexamethasone—psoriasis	1.25e-05	0.000102	CcSEcCtD
Cyclosporine—Nausea—Betamethasone—psoriasis	1.25e-05	0.000102	CcSEcCtD
Cyclosporine—CYP2C8—Metabolism—NDUFA5—psoriasis	1.23e-05	0.000335	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling by GPCR—TYK2—psoriasis	1.23e-05	0.000333	CbGpPWpGaD
Cyclosporine—Urticaria—Methotrexate—psoriasis	1.21e-05	9.92e-05	CcSEcCtD
Cyclosporine—CYP3A5—Metabolism—CYP2S1—psoriasis	1.21e-05	0.000329	CbGpPWpGaD
Cyclosporine—Dizziness—Prednisone—psoriasis	1.21e-05	9.88e-05	CcSEcCtD
Cyclosporine—Abdominal pain—Methotrexate—psoriasis	1.21e-05	9.87e-05	CcSEcCtD
Cyclosporine—Body temperature increased—Methotrexate—psoriasis	1.21e-05	9.87e-05	CcSEcCtD
Cyclosporine—ABCC3—Metabolism—CARM1—psoriasis	1.2e-05	0.000325	CbGpPWpGaD
Cyclosporine—ABCB11—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.17e-05	0.000317	CbGpPWpGaD
Cyclosporine—Vomiting—Prednisone—psoriasis	1.16e-05	9.5e-05	CcSEcCtD
Cyclosporine—Rash—Prednisone—psoriasis	1.15e-05	9.42e-05	CcSEcCtD
Cyclosporine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.15e-05	0.000312	CbGpPWpGaD
Cyclosporine—Dermatitis—Prednisone—psoriasis	1.15e-05	9.41e-05	CcSEcCtD
Cyclosporine—Headache—Prednisone—psoriasis	1.14e-05	9.36e-05	CcSEcCtD
Cyclosporine—FKBP1A—Disease—HLA-A—psoriasis	1.13e-05	0.000306	CbGpPWpGaD
Cyclosporine—PPIA—Disease—CD4—psoriasis	1.13e-05	0.000306	CbGpPWpGaD
Cyclosporine—Hypersensitivity—Methotrexate—psoriasis	1.13e-05	9.2e-05	CcSEcCtD
Cyclosporine—PPP3CA—Immune System—TYK2—psoriasis	1.12e-05	0.000305	CbGpPWpGaD
Cyclosporine—ABCC3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.12e-05	0.000304	CbGpPWpGaD
Cyclosporine—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.12e-05	0.000304	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism—NDUFA5—psoriasis	1.1e-05	0.000299	CbGpPWpGaD
Cyclosporine—Asthenia—Methotrexate—psoriasis	1.1e-05	8.96e-05	CcSEcCtD
Cyclosporine—Nausea—Prednisone—psoriasis	1.09e-05	8.88e-05	CcSEcCtD
Cyclosporine—Pruritus—Methotrexate—psoriasis	1.08e-05	8.84e-05	CcSEcCtD
Cyclosporine—ABCB1—Allograft Rejection—TNF—psoriasis	1.08e-05	0.000292	CbGpPWpGaD
Cyclosporine—ABCB1—Metabolism—NDUFA5—psoriasis	1.08e-05	0.000292	CbGpPWpGaD
Cyclosporine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.07e-05	0.00029	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling by GPCR—CXCL8—psoriasis	1.07e-05	0.00029	CbGpPWpGaD
Cyclosporine—FKBP1A—Disease—APOE—psoriasis	1.05e-05	0.000286	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—IFNG—psoriasis	1.05e-05	0.000285	CbGpPWpGaD
Cyclosporine—CYP2C8—Metabolism—CYP2S1—psoriasis	1.05e-05	0.000285	CbGpPWpGaD
Cyclosporine—Diarrhoea—Methotrexate—psoriasis	1.05e-05	8.55e-05	CcSEcCtD
Cyclosporine—SLCO1A2—Metabolism—CARM1—psoriasis	1.04e-05	0.000283	CbGpPWpGaD
Cyclosporine—PPP3CA—Disease—TYK2—psoriasis	1.04e-05	0.000281	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.03e-05	0.000279	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—CD4—psoriasis	1.02e-05	0.000275	CbGpPWpGaD
Cyclosporine—CYP2D6—Metabolism—NDUFA5—psoriasis	1.01e-05	0.000275	CbGpPWpGaD
Cyclosporine—SLC10A1—Metabolism—APOE—psoriasis	1.01e-05	0.000275	CbGpPWpGaD
Cyclosporine—Dizziness—Methotrexate—psoriasis	1.01e-05	8.26e-05	CcSEcCtD
Cyclosporine—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.01e-05	0.000273	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism—NDUFA5—psoriasis	1.01e-05	0.000273	CbGpPWpGaD
Cyclosporine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1e-05	0.000271	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—SOCS1—psoriasis	9.99e-06	0.000271	CbGpPWpGaD
Cyclosporine—FKBP1A—Disease—NOS2—psoriasis	9.81e-06	0.000266	CbGpPWpGaD
Cyclosporine—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.75e-06	0.000265	CbGpPWpGaD
Cyclosporine—Vomiting—Methotrexate—psoriasis	9.71e-06	7.94e-05	CcSEcCtD
Cyclosporine—Rash—Methotrexate—psoriasis	9.63e-06	7.88e-05	CcSEcCtD
Cyclosporine—Dermatitis—Methotrexate—psoriasis	9.62e-06	7.87e-05	CcSEcCtD
Cyclosporine—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.58e-06	0.00026	CbGpPWpGaD
Cyclosporine—Headache—Methotrexate—psoriasis	9.57e-06	7.82e-05	CcSEcCtD
Cyclosporine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	9.54e-06	0.000259	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—LEP—psoriasis	9.51e-06	0.000258	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—APOE—psoriasis	9.51e-06	0.000258	CbGpPWpGaD
Cyclosporine—PPP3CA—Innate Immune System—IL6—psoriasis	9.43e-06	0.000256	CbGpPWpGaD
Cyclosporine—ABCC1—Metabolism—CARM1—psoriasis	9.39e-06	0.000255	CbGpPWpGaD
Cyclosporine—PPP3CA—Disease—CD4—psoriasis	9.37e-06	0.000254	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism—CYP2S1—psoriasis	9.37e-06	0.000254	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.37e-06	0.000254	CbGpPWpGaD
Cyclosporine—ABCB1—Metabolism—CYP2S1—psoriasis	9.15e-06	0.000248	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—JUN—psoriasis	9.09e-06	0.000247	CbGpPWpGaD
Cyclosporine—Nausea—Methotrexate—psoriasis	9.07e-06	7.42e-05	CcSEcCtD
Cyclosporine—SLCO1B1—Metabolism—CARM1—psoriasis	8.92e-06	0.000242	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—NFKBIA—psoriasis	8.86e-06	0.00024	CbGpPWpGaD
Cyclosporine—SLC10A1—Metabolism—PPARG—psoriasis	8.83e-06	0.00024	CbGpPWpGaD
Cyclosporine—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.78e-06	0.000238	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—NFKB1—psoriasis	8.75e-06	0.000237	CbGpPWpGaD
Cyclosporine—PPIA—Disease—STAT3—psoriasis	8.73e-06	0.000237	CbGpPWpGaD
Cyclosporine—CYP2D6—Metabolism—CYP2S1—psoriasis	8.62e-06	0.000234	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism—CYP2S1—psoriasis	8.55e-06	0.000232	CbGpPWpGaD
Cyclosporine—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.34e-06	0.000226	CbGpPWpGaD
Cyclosporine—ABCG2—Metabolism—CARM1—psoriasis	8.26e-06	0.000224	CbGpPWpGaD
Cyclosporine—CYP3A7—Metabolism—CARM1—psoriasis	8.19e-06	0.000222	CbGpPWpGaD
Cyclosporine—FKBP1A—Disease—TYK2—psoriasis	8.04e-06	0.000218	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—STAT3—psoriasis	7.86e-06	0.000213	CbGpPWpGaD
Cyclosporine—ABCB11—Metabolism—CAT—psoriasis	7.69e-06	0.000209	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—LEP—psoriasis	7.37e-06	0.0002	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—APOE—psoriasis	7.37e-06	0.0002	CbGpPWpGaD
Cyclosporine—ABCC3—Metabolism—CAT—psoriasis	7.37e-06	0.0002	CbGpPWpGaD
Cyclosporine—FKBP1A—Disease—CD4—psoriasis	7.27e-06	0.000197	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—TYK2—psoriasis	7.26e-06	0.000197	CbGpPWpGaD
Cyclosporine—PPP3CA—Disease—STAT3—psoriasis	7.26e-06	0.000197	CbGpPWpGaD
Cyclosporine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	7.09e-06	0.000192	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—NFKBIA—psoriasis	6.87e-06	0.000186	CbGpPWpGaD
Cyclosporine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	6.83e-06	0.000185	CbGpPWpGaD
Cyclosporine—CYP3A4—Metabolism—NDUFA5—psoriasis	6.63e-06	0.00018	CbGpPWpGaD
Cyclosporine—SLCO1A2—Metabolism—CAT—psoriasis	6.42e-06	0.000174	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—CXCL8—psoriasis	6.32e-06	0.000171	CbGpPWpGaD
Cyclosporine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	6.2e-06	0.000168	CbGpPWpGaD
Cyclosporine—PPIA—Disease—IL6—psoriasis	6.1e-06	0.000166	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling by GPCR—IL6—psoriasis	6.01e-06	0.000163	CbGpPWpGaD
Cyclosporine—ABCB11—Metabolism—APOE—psoriasis	5.97e-06	0.000162	CbGpPWpGaD
Cyclosporine—CYP3A5—Metabolism—CARM1—psoriasis	5.92e-06	0.000161	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—JUN—psoriasis	5.87e-06	0.000159	CbGpPWpGaD
Cyclosporine—ABCC1—Metabolism—CAT—psoriasis	5.78e-06	0.000157	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—HLA-A—psoriasis	5.74e-06	0.000156	CbGpPWpGaD
Cyclosporine—ABCC3—Metabolism—APOE—psoriasis	5.73e-06	0.000155	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—NFKB1—psoriasis	5.66e-06	0.000153	CbGpPWpGaD
Cyclosporine—CYP3A4—Metabolism—CYP2S1—psoriasis	5.64e-06	0.000153	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—TYK2—psoriasis	5.63e-06	0.000153	CbGpPWpGaD
Cyclosporine—FKBP1A—Disease—STAT3—psoriasis	5.63e-06	0.000153	CbGpPWpGaD
Cyclosporine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.5e-06	0.000149	CbGpPWpGaD
Cyclosporine—PPP3CA—Immune System—IL6—psoriasis	5.49e-06	0.000149	CbGpPWpGaD
Cyclosporine—SLCO1B1—Metabolism—CAT—psoriasis	5.49e-06	0.000149	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—APOE—psoriasis	5.36e-06	0.000145	CbGpPWpGaD
Cyclosporine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	5.31e-06	0.000144	CbGpPWpGaD
Cyclosporine—ABCB11—Metabolism—PPARG—psoriasis	5.2e-06	0.000141	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—VEGFA—psoriasis	5.13e-06	0.000139	CbGpPWpGaD
Cyclosporine—CYP2C8—Metabolism—CARM1—psoriasis	5.13e-06	0.000139	CbGpPWpGaD
Cyclosporine—ABCG2—Metabolism—CAT—psoriasis	5.08e-06	0.000138	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—STAT3—psoriasis	5.08e-06	0.000138	CbGpPWpGaD
Cyclosporine—PPP3CA—Disease—IL6—psoriasis	5.07e-06	0.000138	CbGpPWpGaD
Cyclosporine—CYP3A7—Metabolism—CAT—psoriasis	5.04e-06	0.000137	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—NOS2—psoriasis	4.99e-06	0.000136	CbGpPWpGaD
Cyclosporine—ABCC3—Metabolism—PPARG—psoriasis	4.99e-06	0.000135	CbGpPWpGaD
Cyclosporine—SLCO1A2—Metabolism—APOE—psoriasis	4.99e-06	0.000135	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.91e-06	0.000133	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—CXCL8—psoriasis	4.9e-06	0.000133	CbGpPWpGaD
Cyclosporine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.79e-06	0.00013	CbGpPWpGaD
Cyclosporine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.68e-06	0.000127	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism—CARM1—psoriasis	4.58e-06	0.000124	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—JUN—psoriasis	4.56e-06	0.000124	CbGpPWpGaD
Cyclosporine—ABCC1—Metabolism—APOE—psoriasis	4.49e-06	0.000122	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.48e-06	0.000122	CbGpPWpGaD
Cyclosporine—ABCB1—Metabolism—CARM1—psoriasis	4.47e-06	0.000121	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—NFKB1—psoriasis	4.38e-06	0.000119	CbGpPWpGaD
Cyclosporine—SLCO1A2—Metabolism—PPARG—psoriasis	4.34e-06	0.000118	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.28e-06	0.000116	CbGpPWpGaD
Cyclosporine—SLCO1B1—Metabolism—APOE—psoriasis	4.26e-06	0.000116	CbGpPWpGaD
Cyclosporine—CYP2D6—Metabolism—CARM1—psoriasis	4.21e-06	0.000114	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism—CARM1—psoriasis	4.17e-06	0.000113	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—TYK2—psoriasis	4.09e-06	0.000111	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—VEGFA—psoriasis	3.98e-06	0.000108	CbGpPWpGaD
Cyclosporine—ABCG2—Metabolism—APOE—psoriasis	3.95e-06	0.000107	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—STAT3—psoriasis	3.94e-06	0.000107	CbGpPWpGaD
Cyclosporine—FKBP1A—Disease—IL6—psoriasis	3.93e-06	0.000107	CbGpPWpGaD
Cyclosporine—CYP3A7—Metabolism—APOE—psoriasis	3.91e-06	0.000106	CbGpPWpGaD
Cyclosporine—ABCC1—Metabolism—PPARG—psoriasis	3.91e-06	0.000106	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.9e-06	0.000106	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—TP53—psoriasis	3.88e-06	0.000105	CbGpPWpGaD
Cyclosporine—SLCO1B1—Metabolism—PPARG—psoriasis	3.71e-06	0.000101	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—CD4—psoriasis	3.7e-06	0.0001	CbGpPWpGaD
Cyclosporine—CYP3A5—Metabolism—CAT—psoriasis	3.64e-06	9.88e-05	CbGpPWpGaD
Cyclosporine—PPP3CA—Signaling Pathways—IL6—psoriasis	3.55e-06	9.63e-05	CbGpPWpGaD
Cyclosporine—ABCG2—Metabolism—PPARG—psoriasis	3.44e-06	9.33e-05	CbGpPWpGaD
Cyclosporine—CYP3A7—Metabolism—PPARG—psoriasis	3.41e-06	9.25e-05	CbGpPWpGaD
Cyclosporine—CYP2C8—Metabolism—CAT—psoriasis	3.15e-06	8.56e-05	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—TP53—psoriasis	3.01e-06	8.16e-05	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—STAT3—psoriasis	2.86e-06	7.77e-05	CbGpPWpGaD
Cyclosporine—CYP3A5—Metabolism—APOE—psoriasis	2.83e-06	7.68e-05	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism—CAT—psoriasis	2.82e-06	7.64e-05	CbGpPWpGaD
Cyclosporine—FKBP1A—Signaling Pathways—IL6—psoriasis	2.75e-06	7.47e-05	CbGpPWpGaD
Cyclosporine—CYP3A4—Metabolism—CARM1—psoriasis	2.75e-06	7.47e-05	CbGpPWpGaD
Cyclosporine—ABCB1—Metabolism—CAT—psoriasis	2.75e-06	7.46e-05	CbGpPWpGaD
Cyclosporine—CYP2D6—Metabolism—CAT—psoriasis	2.59e-06	7.03e-05	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism—CAT—psoriasis	2.57e-06	6.97e-05	CbGpPWpGaD
Cyclosporine—CYP3A5—Metabolism—PPARG—psoriasis	2.46e-06	6.69e-05	CbGpPWpGaD
Cyclosporine—CYP2C8—Metabolism—APOE—psoriasis	2.45e-06	6.65e-05	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism—APOE—psoriasis	2.19e-06	5.94e-05	CbGpPWpGaD
Cyclosporine—ABCB1—Metabolism—APOE—psoriasis	2.14e-06	5.79e-05	CbGpPWpGaD
Cyclosporine—CYP2C8—Metabolism—PPARG—psoriasis	2.13e-06	5.79e-05	CbGpPWpGaD
Cyclosporine—CYP2D6—Metabolism—APOE—psoriasis	2.01e-06	5.46e-05	CbGpPWpGaD
Cyclosporine—ABCC1—Disease—IL6—psoriasis	2e-06	5.43e-05	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism—APOE—psoriasis	1.99e-06	5.41e-05	CbGpPWpGaD
Cyclosporine—CYP2C19—Metabolism—PPARG—psoriasis	1.91e-06	5.17e-05	CbGpPWpGaD
Cyclosporine—ABCB1—Metabolism—PPARG—psoriasis	1.86e-06	5.05e-05	CbGpPWpGaD
Cyclosporine—CYP2D6—Metabolism—PPARG—psoriasis	1.75e-06	4.76e-05	CbGpPWpGaD
Cyclosporine—CYP2C9—Metabolism—PPARG—psoriasis	1.74e-06	4.71e-05	CbGpPWpGaD
Cyclosporine—CYP3A4—Metabolism—CAT—psoriasis	1.69e-06	4.59e-05	CbGpPWpGaD
Cyclosporine—CYP3A4—Metabolism—APOE—psoriasis	1.32e-06	3.57e-05	CbGpPWpGaD
Cyclosporine—CYP3A4—Metabolism—PPARG—psoriasis	1.15e-06	3.11e-05	CbGpPWpGaD
